stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) EBITDA
Elanco Animal Health Incorporated's EBITDA for fiscal 2025 was $695.0M, down 8.91% from $763.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $774.0M. Over the past ten years it has ranged from −$188.0M (fiscal 2020) to $883.0M (fiscal 2022); the current reading is higher than 82% of that period. Elanco Animal Health Incorporated ranks 8th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $695.0M | (8.91%) |
| FY2024 | $763.0M | — |
| FY2023 | −$149.0M | — |
| FY2022 | $883.0M | 128.76% |
| FY2021 | $386.0M | — |
| FY2020 | −$188.0M | — |
| FY2019 | $499.0M | 3.74% |
| FY2018 | $481.0M | 461.26% |
| FY2017 | $85.7M | (62.61%) |
| FY2016 | $229.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $280.0M | (13.85%) |
| Mar 2026 | $325.0M | — |
| Dec 2025 | −$9.0M | — |
| Sep 2025 | $178.0M | (29.64%) |
| 31 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| VTRS Viatris Inc. compare | $2.7B |
| NBIX Neurocrine Biosciences, Inc. compare | $976.5M |
| ELAN Elanco Animal Health Incorporated | $774.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $664.9M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
| LNTH Lantheus Holdings, Inc. compare | $386.4M |
| ALKS Alkermes plc compare | $217.3M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $132.4M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ELAN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement